Core Viewpoint - The company, Liaoning Chengda, has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not provide further large cash injections, focusing instead on attracting strategic investors and shifting its focus towards core industries like biomedicine [1] Group 1: Company Strategy and Management - The new management team, elected in February, is actively optimizing the financing structure and controlling funding costs to ensure stable operations across all business segments [2] - The company has issued short-term financing bonds with decreasing interest rates, indicating a successful reduction in financing costs [2] - The management aims to enhance the company's core competitiveness and sustainable development through non-public issuance of exchangeable bonds [3] Group 2: Financial Performance and Investments - The company has seen significant growth in investment income from its holdings in Guangfa Securities and China Insurance, with year-on-year increases of 53.19% and 143.94%, respectively [4] - The capital market has rebounded, contributing to the increase in asset values and overall financial performance [4] Group 3: Focus on Biomedicine - The company has partnered with the Chinese Academy of Sciences to establish an AI-based vaccine research laboratory, aiming to enhance innovation in vaccine development [6] - Ongoing collaborations with the Chinese Academy of Microbiology focus on infectious disease prevention, with several vaccine candidates in various stages of clinical trials [7] - The company is expanding its vision beyond human vaccines to explore early-stage biopharmaceutical technologies and potential mergers and acquisitions to create a second growth curve [7]

Core Viewpoint - Liaoning Chengda Co., Ltd. has decided to permanently suspend operations at Xinjiang Baoming Mining Co., Ltd. and will not make further large cash investments, focusing instead on introducing strategic investors to address funding and development issues [1] Group 1: Management Changes - The company held its first temporary shareholders' meeting in 2025, where the board of directors was re-elected, and Xu Biao was elected as the chairman [1] - Xu Biao has extensive experience and familiarity with the company, having served on the board since 2020 and currently holding positions in Guangdong Minying Investment Co., Ltd. [1] - Zhang Shanwei, the new president, has a background in industrial investment and management, contributing to the company's strategic direction [2] Group 2: Strategic Focus and Collaborations - The new management team is promoting a culture of achievement and openness, aiming for a shift towards innovative development and technology [2] - Liaoning Chengda's subsidiary, Chengda Bio, has signed a cooperation agreement with Zhongke Zhidong Taichu to establish an "AI + Vaccine Research Joint Laboratory" [2] - A strategic cooperation agreement was also signed with the Institute of Microbiology of the Chinese Academy of Sciences, focusing on emerging infectious diseases [2][3] Group 3: Financial Strategies and Debt Management - The company is optimizing its debt structure and enhancing its financing capabilities, which has led to a reduction in financing costs [3] - In 2025, the company issued short-term financing bonds totaling 14 billion yuan, with decreasing interest rates [3] - The company plans to issue exchangeable bonds to improve resource allocation and strengthen its core competitiveness [4]

Core Viewpoint - The company has decided to permanently suspend its subsidiary Xinjiang Baoming Mining Co., Ltd. due to the inability to obtain necessary permits for land use and production resumption, alongside financial constraints for further investment [1][2]. Financial Performance - In 2024, the company achieved a revenue of 11.289 billion yuan and a net profit attributable to the parent company of 210 million yuan; Xinjiang Baoming generated a revenue of 1.9 million yuan, accounting for 0.17% of the company's total revenue, with a loss of 926 million yuan [2]. - In the first three quarters of 2025, the company reported a revenue of 8.114 billion yuan and a net profit of 1.365 billion yuan; Xinjiang Baoming's revenue was 300,000 yuan, representing 0.03% of the company's total revenue, with a loss of 471 million yuan [2]. Strategic Direction - The company will not continue to invest large amounts of cash into Xinjiang Baoming, as it does not align with its current strategic development direction; efforts will be made to attract strategic investors to address Xinjiang Baoming's financial and developmental issues, although this process is expected to take a long time and carries uncertainties [1]. - During the suspension period, the company will require Xinjiang Baoming to properly manage employee placement and asset maintenance [1].

Core Viewpoint - The company has decided to permanently suspend its subsidiary Xinjiang Baoming Mining Co., Ltd. due to the inability to obtain necessary permits for land use and production resumption, alongside financial constraints for further investment [1][2]. Financial Performance - In 2024, the company achieved an operating revenue of 11.289 billion yuan and a net profit attributable to the parent company of 210 million yuan; Xinjiang Baoming generated an operating revenue of 1.9 million yuan, accounting for 0.17% of the company's total revenue, with a loss of 926 million yuan [2]. - In the first three quarters of 2025, the company reported an operating revenue of 8.114 billion yuan and a net profit attributable to the parent company of 1.365 billion yuan; Xinjiang Baoming's operating revenue was 300,000 yuan, representing 0.03% of the company's total revenue, with a loss of 471 million yuan [2].

关于公司全资子公司向关联参股公司提供担保暨关 联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600739 证券简称：辽宁成大 公告编号：2025-079 辽宁成大股份有限公司 重要内容提示： 担保对象及基本情况 担 保 对 象 被担保人名称 成大医院（大连）有限公司 被担保人关联关系 □控股股东、实际控制人及其控制 的主体 上市公司董事、高级管理人员及其 控制或者任职的主体 □其他______________ 本次担保金额 6,000.00 万元 实际为其提供的担保余额（不含 本次） 6,600.00 万元 是否在前期预计额度内 □是 否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日公司及控股子公司 | | | 已批准的对外担保总额（万元） | 706,600.00 | | （不含本次） | | | 已批准的对外担保总额占公司最 | | | 近一期经 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025－078 一、新疆宝明基本情况 新疆宝明成立于 2005 年 7 月，专门从事油页岩开采、页岩油生产和销售。2010 年 11 月，公司通过增资成为新疆宝明控股股东。截至本公告披露日，新疆宝明基 本情况如下： 1．企业名称：新疆宝明矿业有限公司 辽宁成大股份有限公司 关于控股子公司新疆宝明矿业有限公司长期停产的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辽宁成大股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日召开了第 十一届董事会第八次（临时）会议，审议通过了《关于公司控股子公司新疆宝明 矿业有限公司长期停产的议案》，同意新疆宝明矿业有限公司（以下简称"新疆 宝明"）长期停产。本事项无需提交公司股东会审议。现将具体情况公告如下： 2．企业性质：其他有限责任公司 3．统一社会信用代码：916523277760763443 4．注册地址：新疆昌吉州吉木萨尔县文化西路 21 号 5．法定代表人：裴绍晖 2024 年 1 月 31 日，公司披 ...

证券代码：600739 证券简称：辽宁成大 公告编号：2025-080 注 1：表格中数据尾差为数据四舍五入所致。 公司于近日接到股东广西鑫益信函告，获悉广西鑫益信对其质押的公司部分 股份办理了质押延期购回，具体事宜如下。 1 股东 名称 是否 为控 股股 东 本次质押延 期购回股数 （股） 是否 为限 售股 是否 补充 质押 质押 起始 日 质押 到期 日 延期 后质 押到 期日 质权人 占其所 持股份 比例 占公 司总 股本 比例 质押 融资 资金 用途 广西 鑫益 信商 务服 务有 限公 否 9,000,000 否 否 2023- 07-20 2025- 10-17 2026- 07-17 国泰海 通证券 股份有 限公司 6.91% 0.59% 业务 发展 需要 27,000,000 2023- 07-20 2025- 10-17 2026- 07-17 20.72% 1.77% 1,300,000 2024- 08-22 2025- 10-17 2026- 07-17 1.00% 0.08% 一、本次股份质押延期购回情况 | 司 | | 3,900,000 | | | 2024- | 2025- | ...

辽宁成大股份有限公司（以下简称"公司"）董事会于 2025 年 11 月 18 日 以书面和电子邮件方式发出召开第十一届董事会第八次（临时）会议的通知，会 议于 2025 年 11 月 21 日在公司会议室以通讯方式召开并作出决议。公司董事 9 名，出席会议董事 9 名。会议由董事长徐飚先生主持。会议的召开符合《中华人 民共和国公司法》和《公司章程》的有关规定。会议审议并通过了以下事项： 一、关于公司控股子公司新疆宝明矿业有限公司长期停产的议案 详见《辽宁成大股份有限公司关于控股子公司新疆宝明矿业有限公司长期停 产的公告》（公告编号：2025－078） 表决结果：同意票 9 票、反对票 0 票、弃权票 0 票。 二、关于公司全资子公司向关联参股公司提供担保的议案 证券代码：600739 证券简称：辽宁成大 公告编号：2025－077 辽宁成大股份有限公司 第十一届董事会第八次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本议案已经公司董事会独立董事专门会议审议通过。 详见《辽宁成大股份有限公司关于公司全 ...

Group 1 - The core point of the article is that Liaoning Chengda has received a notice from its shareholder Guangxi Xinyi regarding the extension of the pledge buyback of some shares, with significant implications for the company's shareholding structure and financial health [1] - As of November 21, 2025, Guangxi Xinyi and its concerted parties hold approximately 158 million shares of Liaoning Chengda, accounting for 10.32% of the total share capital, with a total of 132 million shares pledged, representing 83.46% of their holdings and 8.61% of the total share capital [1] - For the first half of 2025, Liaoning Chengda's revenue composition is as follows: import and export trade accounts for 86.64%, biopharmaceuticals for 13.22%, and other sectors for 0.14% [1] Group 2 - The current market capitalization of Liaoning Chengda is 18.1 billion yuan [1]

辽宁成大公告，公司于2025年11月21日召开董事会，审议通过了《关于公司控股子公司新疆宝明矿业有 限公司长期停产的议案》，同意新疆宝明长期停产。2024年度，公司实现营业收入112.89亿元，实现归 属于母公司所有者的净利润2.1亿元；新疆宝明实现营业收入0.19亿元，占公司营业收入的比例为 0.17%，亏损9.26亿元。2025年前三季度，公司实现营业收入81.14亿元，实现归属于母公司所有者的净 利润13.65亿元；新疆宝明实现营业收入0.03亿元，占公司营业收入的比例为0.03%，亏损4.71亿元。 ...